Ona Therapeutics raises $86.6m to advance cancer-drug programmes
Columbus Venture Partners and Mérieux Equity Partners co-lead the Series B for antibody-drug conjugates.
Ona Therapeutics has closed an $86.6 million Series B co-led by Columbus Venture Partners and Mérieux Equity Partners. The June 4 financing will advance its antibody-drug conjugates for cancers that resist existing treatments.
The capital supports clinical development of ONA-255, initially focused on breast cancer, and progression of ONA-389 for colorectal cancer.
Cofides and Korys joined the round alongside Alta Life Sciences, Asabys Partners, Bpifrance, CDTI through SICC Innvierte, FundPlus NV and Ysios Capital. The Barcelona company combines patient-derived target discovery with antibody engineering to develop treatments for advanced cancers.
Use of funds
Clinical development of ONA-255
Advance ONA-389